Cognition Therapeutics CEO and leadership

As a senior executive with 20+ years of sell- and buy- side business and corporate development experience, my career encompasses roles in therapeutics, biotech, genomics, medical devices, and pharmacy benefits. During my tenure at Pfizer, I completed more than 2 dozen acquisition, co-development, and licensing deals ranging from $300M to $7B. Later at Foundation Medicine, I led the $1B sale of their genomics testing to Roche, and earlier played a leadership role in Medco’s $29B sale to Express Scripts. I have worked extensively within R&D environments and launched 3 $1B+ therapeutic products in the hypertension and antibiotics categories. Additionally, I have been the CEO of early stage start-ups, building the funding, commercialization, and exit strategy for therapeutics companies in the CNS and autoimmune disease space.Currently, as CEO of Cognition Therapeutics, I am driving Series C fundraising effort. With multiple phase 2 clinical trials well under way for the Alzheimer’s research and more than a hundred million dollars in dedicated funding, I am repositioning the company to broaden the focus on our science and other CNS clinical conditions. I am pleased to lead a company dedicated to halting neurological disease processes and restoring and preserving the building blocks of brain health and function and look forward to sharing our progress here.

Co-Founder/Chief Science Officer, Cognition Therapeutics ✓CNS Disorders ✓ R&D/Patents ✓Clinical Operations ✓Fundraising

CSO at Cardax / Co-Founder and Chief Chemistry Advisor at Cognition Therapeutics / Drug Development, Los Angeles

Anthony Caggiano is a Chief Medical Officer at Cognition Therapeutics Inc and is based in Pittsburgh, Pennsylvania. He has worked as Acting President and Chief Medical Officer at CONSTANT THERAPEUTICS LLC, Senior Vice President and other positions at ACORDA THERAPEUTICS INC, and Interim Chief Medical Officer at Aeromics. Anthony attended Revivio between 1992 and 1999 and University of Virginia between 1988 and 1992.

Senior executive with diverse finance and accounting experience that includes a strong track record of performance in business operations, planning, information technology and a tour of duty in the National Office of a "Big Four" public accounting firm. Gained exposure to both large and mid-sized public and privately-held companies in various industries including pharmaceutical, medical devices, consumer products, insurance brokerage, high technology, manufacturing and consulting services. Offer a wide range of technical skills, business acumen and entrepreneurial spirit. Hands-on experience in financial management and controls that significantly increase enterprise value. Superior interpersonal skills, capable of resolving complex financial and operational issues and motivating teams to peak performance.

Specialties: - Financial Planning & Analysis

- Process Design & Productivity Initiatives

- Acquistions & Divestitures

- SEC Reporting & Compliance

- Internal Controls & Sarbanes Oxley

- Financial Information Systems (SAP / Oracle)

- Treasury Management & Cash Forecasting

- Team Building & Performance Management

Skilled chief executive, board leader and strategist with proven experience building, managing and financing private and public life science companies from start-up through commercialization. A team builder and leader with strong industry relationships and demonstrated ability to tackle complex situations.

Co-Founder/Chief Science Officer, Cognition Therapeutics ✓CNS Disorders ✓ R&D/Patents ✓Clinical Operations ✓Fundraising

CSO at Cardax / Co-Founder and Chief Chemistry Advisor at Cognition Therapeutics / Drug Development, Los Angeles

As a senior executive with 20+ years of sell- and buy- side business and corporate development experience, my career encompasses roles in therapeutics, biotech, genomics, medical devices, and pharmacy benefits. During my tenure at Pfizer, I completed more than 2 dozen acquisition, co-development, and licensing deals ranging from $300M to $7B. Later at Foundation Medicine, I led the $1B sale of their genomics testing to Roche, and earlier played a leadership role in Medco’s $29B sale to Express Scripts. I have worked extensively within R&D environments and launched 3 $1B+ therapeutic products in the hypertension and antibiotics categories. Additionally, I have been the CEO of early stage start-ups, building the funding, commercialization, and exit strategy for therapeutics companies in the CNS and autoimmune disease space.Currently, as CEO of Cognition Therapeutics, I am driving Series C fundraising effort. With multiple phase 2 clinical trials well under way for the Alzheimer’s research and more than a hundred million dollars in dedicated funding, I am repositioning the company to broaden the focus on our science and other CNS clinical conditions. I am pleased to lead a company dedicated to halting neurological disease processes and restoring and preserving the building blocks of brain health and function and look forward to sharing our progress here.

Co-Founder/Chief Science Officer, Cognition Therapeutics ✓CNS Disorders ✓ R&D/Patents ✓Clinical Operations ✓Fundraising

Skilled chief executive, board leader and strategist with proven experience building, managing and financing private and public life science companies from start-up through commercialization. A team builder and leader with strong industry relationships and demonstrated ability to tackle complex situations.